Search results

IPOs are the lifeblood of venture capital, but they've been few and far between in recent years. Investors are watching to see if the success of some recent high-profile listings will provide a much-needed spark.

Health and biotech VC fundraising surged in the aftermath of the COVID-19 pandemic and has stood strong against market headwinds.

After two-plus years of steady declines, the Series C market may be bouncing back.

These days, investors have more leverage than startups in deal negotiations. How are they choosing to use it?

The geographic diversification of VC has been a developing trend in recent years. Q1 2024 showed a possible reversal.

Learn how to model exit scenarios using waterfall analysis. Waterfalls help investors predict how shareholders would be paid out at a future liquidity event.

At Series D and later, VC deal activity slowed down in Q1 2024. There are reasons for the decline on both sides of the negotiating table.

Learn how to calculate net and gross TVPI (total value to paid-in capital), key metrics investors and fund managers use to evaluate a fund’s performance.

The venture capital fundraising market remained slow in Q1 2024, but valuations held steady or climbed at almost every stage.

Carta's connected platform gives GPs, LPs, fund CFOs, and their fund administration partners unprecedented transparency into fund transactions.

Fundraising for pre-seed companies stayed robust in Q1 2024, dominated by SAFEs and convertible notes; valuation caps remained flat.